Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 3, 2005, Pages 598-603

  Sironi, Luigi ^a   Gianazza, Elisabetta ^a   Gelosa, Paolo ^a   Guerrini, Uliano ^a   Nobili, Elena ^a   Gianella, Anita ^a   Cremonesi, Benedetta ^a   Paoletti, Rodolfo ^a   Tremoli, Elena ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Brain ischemia; Inflammation; Proteome; Rats; Rosuvastatin; Simvastatin; Statins; Stroke prone rats

Indexed keywords

CHEMOATTRACTANT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; MESSENGER RNA; ROSUVASTATIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; BRAIN BLOOD VESSEL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HYDROPHILICITY; HYDROPHOBICITY; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE;

ACUTE-PHASE PROTEINS; ANIMALS; CEREBRAL ARTERIES; CEREBROVASCULAR ACCIDENT; CHEMOKINE CCL2; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; P-SELECTIN; PROTEINURIA; PYRIMIDINES; RATS; RATS, INBRED SHR; RNA, MESSENGER; SIMVASTATIN; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 14644432487     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000157145.98200.55     Document Type: Article

References (32)

1. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998:11: 45-49.
2. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-294.
3. Anuk T, Assayag EB, Rotstein R, Fusman R, Zeltser D, Berliner S, Avitzour D, Shapira I, Arber N, Bornstein NM. Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol Scand. 2002;106:196-199.
4. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, Gianazza E. Acute-phase proteins before cerebral ischemia in stroke-prone rats. Identification by proteomics. Stroke. 2001;32:753-756.
5. van Mil AHM, Westendorp RGJ, Bollen EL, Lagaay AM, Blauw GJ. HMG-CoA reductase inhibitors in the prevention of stroke. Drugs. 2000;59:1-6.
6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Aterioscler Thromb Vasc Biol. 2001; 21:1712-1719.
7. Egashira K, Ni W, Inoue S, Kataoka C, Kitamoto S, Koyanagi M, Takeshita A. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res. 2000;23:353-358.
8. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Phannacol Exp Ther. 2000;294:1043-1046.
9. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22:1524-1534.
10. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001;133:406-412.
11. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory response in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001;1:105-118.
12. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
13. Smith G, Davidson R, Bloor S, Burns K, McAulay P, Torr N, Ward W, McTaggart F. Pharmacological properties of ZD4522 - a new HMG-CoA reductase inhibitor. Atherosclerosis. 2000;151:39.
14. Gianazza E. Casting immobilized pH gradients. In: Link AJ, ed. 2-D Proteome Analysis Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 1998.
15. Balduini W, Mazzoni E, Carloni S, De Simoni MG, Perego C, Sironi L, Cimino M. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke. 2003;34:2007-2012.
16. Yamada M, Sasaki R, Sato N, Suzuki M, Tamura M, Matsushita T et al. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur J Pharmacol. 2002;449:167-176.
17. Keilhoff G, Seidel B, Noack H, Tischmeyer W, Stanek D, Wolf G. Patterns of nitric oxide synthase at the messenger RNA and protein levels during early rat brain development. Neuroscience. 1996;75:1193-1201.
18. Jones SP, Gibson MF, Rimmer III DM, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002;40:1172-1178.
19. Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, Baumann H, Genco RJ, De Nardin E. Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol. 2002;9:425-432.
20. Blezer EL, Nicolay K, Goldschmeding R et al. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension. 1999;33:137-144.
21. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232-237.
22. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
23. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1997;17:1345-1349.
24. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
25. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
26. Kinlay S, Rifai N, Libby P, Ganz P. Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: a substudy of the MIRACL trial. J Am Coll Cardiol. 2000;39:304A.
27. Urban J, Chan D, Schreiber G. A rat serum glycoprotein whose synthesis rate increases greatly during inflammation. J Biol Chem. 1979;254: 10565-10568.
28. Sironi L, Guerrini U, Tremoli E, Miller I, Gelosa P, Lascialfari A, Zucca I, Eberini I, Gemeiner M, Paoletti R, Gianazza E. Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomic and magnetic resonance imaging approach. J Neurosci Res. 2004;78:115-122.
29. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20:131-147.
30. Sironi L, Calvio AM, Bellosta S, Lodetti B, Guerrini U, Monetti M, Tremoli E, Mussoni L. Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res. 2003;974:184-192.
31. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, Holschermann H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41:397-401.
32. Matsumoto M, Einhaus D, Gold ES, Aderem A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. Immunol. 2004;172:7377-7384.